Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Codrici, Elena ^a   Enciu, Ana Maria ^a,b   Popescu, Ionela Daniela ^a   Mihai, Simona ^a   Tanase, Cristiana ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; CEDIRANIB; CELL MARKER; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; INTERLEUKIN 6; MICRORNA; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; PLERIXAFOR; PROMININ 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL COMMUNICATION; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL HETEROGENEITY; CELL HYPOXIA; CELL INTERACTION; CELL LINEAGE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOMA STEM CELL; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; NEURAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; STEM CELL SELF-RENEWAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84959112873     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/5728438     Document Type: Review

References (211)

1. R. Stupp, M. E. Hegi, W. P. Mason et al., "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial," The Lancet Oncology, vol. 10, no. 5, pp. 459-466, 2009.
2. M. E. Hardee and D. Zagzag, "Mechanisms of glioma-associated neovascularization," The American Journal of Pathology, vol. 181, no. 4, pp. 1126-1141, 2012.
3. A. L. Vescovi, R. Galli, and B. A. Reynolds, "Brain tumour stem cells," Nature Reviews Cancer, vol. 6, no. 6, pp. 425-436, 2006.
4. D. L. Schonberg, D. Lubelski, T. E. Miller et al., "Brain tumor stem cells: molecular characteristics and their impact on therapy," Molecular Aspects of Medicine, vol. 39, pp. 82-101, 2014.
5. R. Galli, E. Binda, U. Orfanelli et al., "Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma," Cancer Research, vol. 64, no. 19, pp. 7011-7021, 2004.
6. D. Beier, B. Schriefer, K. Brawanski et al., "Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines," Journal of Neuro-Oncology, vol. 109, no. 1, pp. 45-52, 2012.
7. J. Chen, Y. Li, T.-S. Yu et al., "A restricted cell population propagates glioblastoma growth after chemotherapy," Nature, vol. 488, no. 7412, pp. 522-526, 2012.
8. J. D. Lathia, J. Gallagher, J. T. Myers et al., "Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells," PLoS ONE, vol. 6, no. 9, Article ID e24807, 2011.
9. C. Calabrese, H. Poppleton, M. Kocak et al., "A perivascular niche for brain tumor stem cells," Cancer Cell, vol. 11, no. 1, pp. 69-82, 2007.
10. Z. Li, S. Bao, Q. Wu et al., "Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells," Cancer Cell, vol. 15, no. 6, pp. 501-513, 2009.
11. T. S. Zhu, M. A. Costello, C. E. Talsma et al., "Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells," Cancer Research, vol. 71, no. 18, pp. 6061-6072, 2011.
12. D. W. Infanger, Y. Cho, B. S. Lopez et al., "Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche," Cancer Research, vol. 73, no. 23, pp. 7079-7089, 2013.
13. E. M. Galan-Moya, A. Le Guelte, E. L. Fernandes et al., "Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway," EMBO Reports, vol. 12, no. 5, pp. 470-476, 2011.
14. R. Wang, K. Chadalavada, J. Wilshire et al., "Glioblastoma stem-like cells give rise to tumour endothelium," Nature, vol. 468, no. 7325, pp. 829-833, 2010.
15. L. Ricci-Vitiani, R. Pallini, M. Biffoni et al., "Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells," Nature, vol. 468, no. 7325, pp. 824-830, 2010.
16. L. Cheng, Z. Huang, W. Zhou et al., "Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth," Cell, vol. 153, no. 1, pp. 139-152, 2013.
17. P. O. Guichet, S. Guelfi, M. Teigell et al., "Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells," Stem Cells, vol. 33, no. 1, pp. 21-34, 2015.
18. D. Chroscinski, D. Sampey, and N. Maherali, "Registered report: tumour vascularization via endothelial differentiation of glioblastoma stem-like cells," eLife, vol. 4, 2015.
19. S. Bao, Q. Wu, S. Sathornsumetee et al., "Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor," Cancer Research, vol. 66, no. 16, pp. 7843-7848, 2006.
20. C. Folkins, Y. Shaked, S. Man et al., "Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1," Cancer Research, vol. 69, no. 18, pp. 7243-7251, 2009.
21. C. Thirant, E.-M. Galan-Moya, L. G. Dubois et al., "Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor," STEM CELLS, vol. 30, no. 5, pp. 845-853, 2012.
22. S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, "Cancer stem cells in nervous system tumors," Oncogene, vol. 23, no. 43, pp. 7267-7273, 2004.
23. R. M. R. Gangemi, F. Griffero, D. Marubbi et al., "SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity," STEM CELLS, vol. 27, no. 1, pp. 40-48, 2009.
24. high glioma-initiating cell population in human glioblastoma," Cancer Cell, vol. 18, no. 6, pp. 655-668, 2010.
25. J. D. Lathia, J. Gallagher, J. M. Heddleston et al., "Integrin alpha 6 regulates glioblastoma stem cells," Cell Stem Cell, vol. 6, no. 5, pp. 421-432, 2010.
26. + cells correlates with malignancy of gliomas," Molecular and Cellular Neuroscience, vol. 43, no. 1, pp. 51-59, 2010.
27. D. Bexell, S. Gunnarsson, P. Siesjö, J. Bengzon, and A. Darabi, "CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas," International Journal of Cancer, vol. 125, no. 1, pp. 15-22, 2009.
28. M. Zhang, T. Song, L. Yang et al., "Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients," Journal of Experimental and Clinical Cancer Research, vol. 27, no. 1, article 85, 2008.
29. Y. Guo, S. Liu, P. Wang et al., "Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas," Histopathology, vol. 59, no. 4, pp. 763-775, 2011.
30. J. Mathieu, Z. Zhang, W. Zhou et al., "HIF induces human embryonic stem cell markers in cancer cells," Cancer Research, vol. 71, no. 13, pp. 4640-4652, 2011.
31. C.-S. Niu, D.-X. Li, Y.-H. Liu, X.-M. Fu, S.-F. Tang, and J. Li, "Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells," Oncology Reports, vol. 26, no. 3, pp. 593-601, 2011.
32. H. Ikushima, T. Todo, Y. Ino et al., "Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein," Journal of Biological Chemistry, vol. 286, no. 48, pp. 41434-41441, 2011.
33. Y. Ge, F. Zhou, H. Chen et al., "Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells," Biochemical and Biophysical Research Communications, vol. 397, no. 4, pp. 711-717, 2010.
34. D. Hägerstrand, X. He, M. Bradic Lindh et al., "Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile," Neuro-Oncology, vol. 13, no. 11, pp. 1178-1191, 2011.
35. S. Bao, Q. Wu, R. E. McLendon et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response," Nature, vol. 444, no. 7120, pp. 756-760, 2006.
36. + cancer stem cells in glioblastoma," Molecular Cancer, vol. 5, article 67, 2006.
37. S. C. Li, L. T. Vu, H. W. Ho et al., "Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall," Cancer Cell International, vol. 12, no. 1, article 41, 2012.
38. Q. Huang, Q.-B. Zhang, J. Dong et al., "Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro," BMC Cancer, vol. 8, article 304, 2008.
39. P. Ø. Sakariassen, H. Immervoll, and M. Chekenya, "Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies," Neoplasia, vol. 9, no. 11, pp. 882-892, 2007.
40. J. Wang, T. P. Wakeman, J. D. Lathia et al., "Notch promotes radioresistance of glioma stem cells," STEM CELLS, vol. 28, no. 1, pp. 17-28, 2010.
41. S. K. Singh, I. D. Clarke, M. Terasaki et al., "Identification of a cancer stem cell in human brain tumors," Cancer Research, vol. 63, no. 18, pp. 5821-5828, 2003.
42. S. K. Singh, C. Hawkins, I. D. Clarke et al., "Identification of human brain tumour initiating cells," Nature, vol. 432, no. 7015, pp. 396-401, 2004.
43. K.-I. Mizutani, K. Yoon, L. Dang, A. Tokunaga, and N. Gaiano, "Differential Notch signalling distinguishes neural stem cells from intermediate progenitors," Nature, vol. 449, no. 7160, pp. 351-355, 2007.
44. J. S. Tchorz, M. Tome, D. Cloëtta et al., "Constitutive Notch2 signaling in neural stem cells promotes tumorigenic features and astroglial lineage entry," Cell Death and Disease, vol. 3, article e325, 2012.
45. C.-H. Yoon, M.-J. Kim, R.-K. Kim et al., "c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells," Oncogene, vol. 31, no. 44, pp. 4655-4666, 2012.
46. V. Clement, P. Sanchez, N. de Tribolet, I. Radovanovic, and A. Ruiz i Altaba, "HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity," Current Biology, vol. 17, no. 2, pp. 165-172, 2007.
47. M. Ehtesham, K. Y. Mapara, C. B. Stevenson, and R. C. Thompson, "CXCR4 mediates the proliferation of glioblastoma progenitor cells," Cancer Letters, vol. 274, no. 2, pp. 305-312, 2009.
48. R. Bonavia, M. M. Inda, S. Vandenberg et al., "EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway," Oncogene, vol. 31, no. 36, pp. 4054-4066, 2012.
49. X. Jin, J. Yin, S.-H. Kim et al., "EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction," Cancer Research, vol. 71, no. 22, pp. 7125-7134, 2011.
50. H. Wang, J. D. Lathia, Q. Wu et al., "Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth," STEM CELLS, vol. 27, no. 10, pp. 2393-2404, 2009.
51. E. L. Jackson, J. M. Garcia-Verdugo, S. Gil-Perotin et al., "PDGFRα-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling," Neuron, vol. 51, no. 2, pp. 187-199, 2006.
52. J. Lee, M. J. Son, K. Woolard et al., "Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells," Cancer Cell, vol. 13, no. 1, pp. 69-80, 2008.
53. S. G. M. Piccirillo, B. A. Reynolds, N. Zanetti et al., "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells," Nature, vol. 444, no. 7120, pp. 761-765, 2006.
54. A. Ruiz i Altaba, C. Mas, and B. Stecca, "The Gli code: an information nexus regulating cell fate, stemness and cancer," Trends in Cell Biology, vol. 17, no. 9, pp. 438-447, 2007.
55. E. E. Bar, A. Chaudhry, A. Lin et al., "Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma," STEM CELLS, vol. 25, no. 10, pp. 2524-2533, 2007.
56. Y. Xin, S.-Y. Hao, Y.-J. Tian et al., "Expression and significance of sonic hedgehog signaling pathway-related components in brainstem and supratentorial astrocytomas," Chinese Medical Journal, vol. 124, no. 21, pp. 3515-3520, 2011.
57. M. L. Cruceru, M. Neagu, J.-B. Demoulin, and S. N. Constantinescu, "Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms," Journal of Cellular and Molecular Medicine, vol. 17, no. 10, pp. 1218-1235, 2013.
58. A. Filatova, T. Acker, and B. K. Garvalov, "The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment," Biochimica et Biophysica Acta - General Subjects, vol. 1830, no. 2, pp. 2496-2508, 2013.
59. H. Ikushima, T. Todo, Y. Ino, M. Takahashi, K. Miyazawa, and K. Miyazono, "Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors," Cell Stem Cell, vol. 5, no. 5, pp. 504-514, 2009.
60. R. Schüle, C. Dictus, B. Campos et al., "Potential canonical wnt pathway activation in high-grade astrocytomas," The Scientific World Journal, vol. 2012, Article ID 697313, 11 pages, 2012.
61. V. Häyry, O. Tynninen, H. K. Haapasalo et al., "Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours," Neuropathology and Applied Neurobiology, vol. 34, no. 5, pp. 555-563, 2008.
62. S. Facchino, M. Abdouh, W. Chatoo, and G. Bernier, "BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery," The Journal of Neuroscience, vol. 30, no. 30, pp. 10096-10111, 2010.
63. M. Zbinden, A. Duquet, A. Lorente-Trigos, S.-N. Ngwabyt, I. Borges, and A. Ruiz I Altaba, "NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53," The EMBO Journal, vol. 29, no. 15, pp. 2659-2674, 2010.
64. L. Cheng, S. Bao, and J. N. Rich, "Potential therapeutic implications of cancer stem cells in glioblastoma," Biochemical Pharmacology, vol. 80, no. 5, pp. 654-665, 2010.
65. Y. Yoshida, K. Takahashi, K. Okita, T. Ichisaka, and S. Yamanaka, "Hypoxia enhances the generation of induced pluripotent stem cells," Cell Stem Cell, vol. 5, no. 3, pp. 237-241, 2009.
66. K. L. Ligon, J. A. Alberta, A. T. Kho et al., "The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas," Journal of Neuropathology and Experimental Neurology, vol. 63, no. 5, pp. 499-509, 2004.
67. L. E. Barrett, Z. Granot, C. Coker et al., "Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma," Cancer Cell, vol. 21, no. 1, pp. 11-24, 2012.
68. A. Wu, J. Wei, L.-Y. Kong et al., "Glioma cancer stem cells induce immunosuppressive macrophages/microglia," Neuro Oncology, vol. 12, no. 11, pp. 1113-1125, 2010.
69. G.-H. Li, H. Wei, S.-Q. Lv, H. Ji, and D.-L. Wang, "Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells," International Journal of Oncology, vol. 37, no. 1, pp. 103-110, 2010.
70. M. M. Sherry, A. Reeves, J. K. Wu, and B. H. Cochran, "STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells," STEM CELLS, vol. 27, no. 10, pp. 2383-2392, 2009.
71. A. C. deCarvalho, K. Nelson, N. Lemke et al., "Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo," STEM CELLS, vol. 28, no. 2, pp. 181-190, 2010.
72. M. Visani, D. de Biase, G. Marucci et al., "Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III," Molecular Oncology, vol. 8, no. 2, pp. 417-430, 2014.
73. E. V. Makeyev, J. Zhang, M. A. Carrasco, and T. Maniatis, "The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing," Molecular Cell, vol. 27, no. 3, pp. 435-448, 2007.
74. Y. Zhang, A. Dutta, and R. Abounader, "The role of microRNAs in glioma initiation and progression," Frontiers in Bioscience, vol. 17, no. 2, pp. 700-712, 2012.
75. J. Silber, A. Jacobsen, T. Ozawa et al., "miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis," PLoS ONE, vol. 7, no. 3, Article ID e33844, 2012.
76. H. Gal, G. Pandi, A. A. Kanner et al., "MIR-451 and imatinib mesylate inhibit tumor growth of Glioblastoma stem cells," Biochemical and Biophysical Research Communications, vol. 376, no. 1, pp. 86-90, 2008.
77. M. Smits, J. Nilsson, S. E. Mir et al., "miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis," Oncotarget, vol. 1, no. 8, pp. 710-720, 2010.
78. Y. Tu, X. Gao, G. Li et al., "MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1," Cancer Research, vol. 73, no. 19, pp. 6046-6055, 2013.
79. J. Godlewski, M. O. Nowicki, A. Bronisz et al., "MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells," Molecular Cell, vol. 37, no. 5, pp. 620-632, 2010.
80. X. Zhou, J. Zhang, Q. Jia et al., "Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3," Oncology Reports, vol. 24, no. 1, pp. 195-201, 2010.
81. F. Zhi, X. Chen, S. Wang et al., "The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma," European Journal of Cancer, vol. 46, no. 9, pp. 1640-1649, 2010.
82. L. Sun, W. Yan, Y. Wang et al., "MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10," Brain Research, vol. 1389, pp. 9-18, 2011.
83. B. Malzkorn, M. Wolter, F. Liesenberg et al., "Identification and functional characterization of microRNAs involved in the malignant progression of gliomas," Brain Pathology, vol. 20, no. 3, pp. 539-550, 2010.
84. S. A. M. Rao, V. Santosh, and K. Somasundaram, "Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma," Modern Pathology, vol. 23, no. 10, pp. 1404-1417, 2010.
85. N. Wu, L. Xiao, X. Zhao et al., "miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2," FEBS Letters, vol. 586, no. 21, pp. 3831-3839, 2012.
86. L. Shi, Y. Wan, G. Sun et al., "Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells," NeuroMolecular Medicine, vol. 14, no. 4, pp. 303-316, 2012.
87. Y. Guan, M. Mizoguchi, K. Yoshimoto et al., "MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance," Clinical Cancer Research, vol. 16, no. 16, pp. 4289-4297, 2010.
88. H. Yan, D. W. Parsons, G. Jin et al., "IDH1 and IDH2 mutations in gliomas," The New England Journal of Medicine, vol. 360, no. 8, pp. 765-773, 2009.
89. H. He, C. S. Niu, and M. W. Li, "Correlation between glioblastoma stem-like cells and tumor vascularization," Oncology Reports, vol. 27, no. 1, pp. 45-50, 2011.
90. K. B. Pointer, P. A. Clark, M. Zorniak, B. M. Alrfaei, and J. S. Kuo, "Glioblastoma cancer stem cells: biomarker and therapeutic advances," Neurochemistry International, vol. 71, no. 1, pp. 1-7, 2014.
91. F. Gambelli, F. Sasdelli, I. Manini et al., "Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression," Cell Biology International, vol. 36, no. 1, pp. 29-38, 2012.
92. - glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles," Cancer Research, vol. 67, no. 9, pp. 4010-4015, 2007.
93. K. M. Joo, S. Y. Kim, X. Jin et al., "Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas," Laboratory Investigation, vol. 88, no. 8, pp. 808-815, 2008.
94. T. Yang and K. Rycaj, "Targeted therapy against cancer stem cells," Oncology Letters, vol. 10, no. 1, pp. 27-33, 2015.
95. R. Chen, M. C. Nishimura, S. M. Bumbaca et al., "A hierarchy of self-renewing tumor-initiating cell types in glioblastoma," Cancer Cell, vol. 17, no. 4, pp. 362-375, 2010.
96. P. Brescia, B. Ortensi, L. Fornasari, D. Levi, G. Broggi, and G. Pelicci, "CD133 is essential for glioblastoma stem cell maintenance," STEM CELLS, vol. 31, no. 5, pp. 857-869, 2013.
97. B. Wu, C. Sun, F. Feng, M. Ge, and L. Xia, "Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis," Journal of Experimental & Clinical Cancer Research, vol. 34, article 44, 2015.
98. R. Pallini, L. Ricci-Vitiani, G. L. Banna et al., "Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme," Clinical Cancer Research, vol. 14, no. 24, pp. 8205-8212, 2008.
99. - glioblastoma-derived cancer stem cell lines suggest different cells of origin," Cancer Research, vol. 70, no. 5, pp. 2030-2040, 2010.
100. U. R. Chandran, S. Luthra, L. Santana-Santos et al., "Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells," Genomics Data, vol. 5, pp. 333-336, 2015.
101. I. Saga, S. Shibao, J. Okubo et al., "Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model," Neuro-Oncology, vol. 16, no. 8, pp. 1048-1056, 2014.
102. M. Meyer, J. Reimand, X. Lan et al., "Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 3, pp. 851-856, 2015.
103. B. B. Endaya, P. Y. P. Lam, A. C. B. Meedeniya, and J. Neuzil, "Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model," Molecular Oncology, vol. 10, no. 1, pp. 126-137, 2016.
104. M. Sugimori, Y. Hayakawa, B. M. Boman et al., "Discovery of power-law growth in the self-renewal of heterogeneous glioma stem cell populations," PLoS ONE, vol. 10, no. 8, Article ID e0135760, 2015.
105. + niches and single cells in glioblastoma have different phenotypes," Journal of Neuro-Oncology, vol. 104, no. 1, pp. 129-143, 2011.
106. R. K. Jain, E. di Tomaso, D. G. Duda, J. S. Loeffler, A. G. Sorensen, and T. T. Batchelor, "Angiogenesis in brain tumours," Nature Reviews Neuroscience, vol. 8, no. 8, pp. 610-622, 2007.
107. P. Carmeliet and R. K. Jain, "Angiogenesis in cancer and other diseases," Nature, vol. 407, no. 6801, pp. 249-257, 2000.
108. + glioma stem cells to temozolomide therapy," Molecular Medicine, vol. 17, no. 1-2, pp. 103-112, 2011.
109. G.-N. Yan, L. Yang, Y.-F. Lv et al., "Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway," Journal of Pathology, vol. 234, no. 1, pp. 11-22, 2014.
110. O. J. Becher, D. Hambardzumyan, E. I. Fomchenko et al., "Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas," Cancer Research, vol. 68, no. 7, pp. 2241-2249, 2008.
111. K. Toyoda, K. Tanaka, S. Nakagawa et al., "Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model," Cellular and Molecular Neurobiology, vol. 33, no. 4, pp. 489-501, 2013.
112. P. Wang, H. Zhen, J. Zhang et al., "Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo," Molecular Carcinogenesis, vol. 51, no. 7, pp. 586-595, 2012.
113. S. M. Pollard, K. Yoshikawa, I. D. Clarke et al., "Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens," Cell Stem Cell, vol. 4, no. 6, pp. 568-580, 2009.
114. K.-W. Chang, Y.-L. Huang, Z.-R. Wong et al., "Fibroblast growth factor-2 up-regulates the expression of nestin through the Ras-Raf-ERK-Sp1 signaling axis in C6 glioma cells," Biochemical and Biophysical Research Communications, vol. 434, no. 4, pp. 854-860, 2013.
115. G. Li, Z. Chen, Y.-D. Hu et al., "Autocrine factors sustain glioblastoma stem cell self-renewal," Oncology Reports, vol. 21, no. 2, pp. 419-424, 2009.
116. E. M. Haley and Y. Kim, "The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture," Cancer Letters, vol. 346, no. 1, pp. 1-5, 2014.
117. A. Pietras, A. M. Katz, E. J. Ekström et al., "Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth," Cell Stem Cell, vol. 14, no. 3, pp. 357-369, 2014.
118. S. R. Chirasani, A. Sternjak, P. Wend et al., "Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells," Brain, vol. 133, no. 7, pp. 1961-1972, 2010.
119. N. Barabutis and A. V. Schally, "Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology," Cell Cycle, vol. 9, no. 20, pp. 4110-4116, 2010.
120. H. Kiaris, I. Chatzistamou, A. G. Papavassiliou, and A. V. Schally, "Growth hormone-releasing hormone: not only a neurohormone," Trends in Endocrinology and Metabolism, vol. 22, no. 8, pp. 311-317, 2011.
121. Z.-J. Liu, T. Shirakawa, Y. Li et al., "Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis," Molecular and Cellular Biology, vol. 23, no. 1, pp. 14-25, 2003.
122. I. B. Lobov, R. A. Renard, N. Papadopoulos et al., "Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3219-3224, 2007.
123. N. Charles, T. Ozawa, M. Squatrito et al., "Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells," Cell Stem Cell, vol. 6, no. 2, pp. 141-152, 2010.
124. C. E. Eyler, Q. Wu, K. Yan et al., "Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2," Cell, vol. 146, no. 1, pp. 53-66, 2011.
125. M. Scharpfenecker, J. J. C. M. Kruse, D. Sprong, N. S. Russell, P. ten Dijke, and F. A. Stewart, "Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells," International Journal of Radiation Oncology, Biology, Physics, vol. 73, no. 2, pp. 506-513, 2009.
126. Y.-F. Ping, X. Zhang, and X.-W. Bian, "Cancer stem cells and their vascular niche: do they benefit from each other?" Cancer Letters, 2015.
127. Q. Shen, Y. Wang, E. Kokovay et al., "Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions," Cell Stem Cell, vol. 3, no. 3, pp. 289-300, 2008.
128. P. Huang, M. R. S. Rani, M. S. Ahluwalia et al., "Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma," Cancer Research, vol. 72, no. 6, pp. 1428-1437, 2012.
129. X. Zheng, Q. Xie, S. Li, and W. Zhang, "CXCR4-positive subset of glioma is enriched for cancer stem cells," Oncology Research, vol. 19, no. 12, pp. 555-561, 2012.
130. R. Würth, A. Bajetto, J. K. Harrison, F. Barbieri, and T. Florio, "CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment," Frontiers in Cellular Neuroscience, vol. 8, article 144, 2014.
131. D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolfi, K. Manova-Todorova, and E. C. Holland, "PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo," Genes & Development, vol. 22, no. 4, pp. 436-448, 2008.
132. W. B. Saunders, B. L. Bohnsack, J. B. Faske et al., "Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3," The Journal of Cell Biology, vol. 175, no. 1, pp. 179-191, 2006.
133. P. C. Stapor, R. S. Sweat, D. C. Dashti, A. M. Betancourt, and W. L. Murfee, "Pericyte dynamics during angiogenesis: new insights from new identities," Journal of Vascular Research, vol. 51, no. 3, pp. 163-174, 2014.
134. J. T. Durham, H. K. Surks, B. M. Dulmovits, and I. M. Herman, "Pericyte contractility controls endothelial cell cycle progression and sprouting: insights into angiogenic switch mechanics," The American Journal of Physiology - Cell Physiology, vol. 307, no. 9, pp. C878-C892, 2014.
135. A. L. Ribeiro and O. K. Okamoto, "Combined effects of pericytes in the tumor microenvironment," Stem Cells International, vol. 2015, Article ID 868475, 8 pages, 2015.
136. Y. Soda, T. Marumoto, D. Friedmann-Morvinski et al., "Transdifferentiation of glioblastoma cells into vascular endothelial cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 11, pp. 4274-4280, 2011.
137. M.-T. Chiao, Y.-C. Yang, W.-Y. Cheng, C.-C. Shen, and J.-L. Ko, "CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo," Current Neurovascular Research, vol. 8, no. 3, pp. 210-219, 2011.
138. F. J. Rodriguez, B. A. Orr, K. L. Ligon, and C. G. Eberhart, "Neoplastic cells are a rare component in human glioblastoma microvasculature," Oncotarget, vol. 3, no. 1, pp. 98-106, 2012.
139. S. El Hallani, B. Boisselier, F. Peglion et al., "A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry," Brain, vol. 133, no. 4, pp. 973-982, 2010.
140. S. El Hallani, C. Colin, Y. El Houfi et al., "Tumor and endothelial cell hybrids participate in glioblastoma vasculature," BioMed Research International, vol. 2014, Article ID 827327, 9 pages, 2014.
141. P.-P. Zheng, M. van der Weiden, P. J. van der Spek, A. J. P. E. Vincent, and J. M. Kros, "Intratumoral, not circulating, endothelial progenitor cells share genetic aberrations with glial tumor cells," Journal of Cellular Physiology, vol. 228, no. 7, pp. 1383-1390, 2013.
142. N. Jhaveri, T. C. Chen, and F. M. Hofman, "Tumor vasculature and glioma stem cells: contributions to glioma progression," Cancer Letters, 2014.
143. J. M. Heddleston, Z. Li, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich, "The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype," Cell Cycle, vol. 8, no. 20, pp. 3274-3284, 2009.
144. S. M. Wood, J. M. Gleadle, C. W. Pugh, O. Hankinson, and P. J. Ratcliffe, "The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxie induction of gene expression: studies in arnt-deficient cells," The Journal of Biological Chemistry, vol. 271, no. 25, pp. 15117-15123, 1996.
145. L. Holmquist-Mengelbier, E. Fredlund, T. Löfstedt et al., "Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype," Cancer Cell, vol. 10, no. 5, pp. 413-423, 2006.
146. G. Peng and Y. Liu, "Hypoxia-inducible factors in cancer stem cells and inflammation," Trends in Pharmacological Sciences, vol. 36, no. 6, pp. 374-383, 2015.
147. L. Yang, C. Lin, L. Wang, H. Guo, and X. Wang, "Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications," Experimental Cell Research, vol. 318, no. 19, pp. 2417-2426, 2012.
148. K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," Cell, vol. 131, no. 5, pp. 861-872, 2007.
149. K. L. Covello, J. Kehler, H. Yu et al., "HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth," Genes and Development, vol. 20, no. 5, pp. 557-570, 2006.
150. V. Moreno-Manzano, F. J. Rodríguez-Jiménez, J. L. Aceña-Bonilla et al., "FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status," The Journal of Biological Chemistry, vol. 285, no. 2, pp. 1333-1342, 2010.
151. J. D. Gordan, J. A. Bertout, C.-J. Hu, J. A. Diehl, and M. C. Simon, "HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity," Cancer Cell, vol. 11, no. 4, pp. 335-347, 2007.
152. M. Toda, "Glioma stem cells and immunotherapy for the treatment of malignant gliomas," ISRN Oncology, vol. 2013, Article ID 673793, 13 pages, 2013.
153. K. De Bock, M. Mazzone, and P. Carmeliet, "Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?" Nature Reviews Clinical Oncology, vol. 8, no. 7, pp. 393-404, 2011.
154. M. Pàez-Ribes, E. Allen, J. Hudock et al., "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis," Cancer Cell, vol. 15, no. 3, pp. 220-231, 2009.
155. T. K. Mackey, R. Cuomo, C. Guerra, and B. A. Liang, "After counterfeit Avastin® - what have we learned and what can be done?" Nature Reviews Clinical Oncology, vol. 12, no. 5, pp. 302-308, 2015.
156. R. Du, K. V. Lu, C. Petritsch et al., "HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion," Cancer Cell, vol. 13, no. 3, pp. 206-220, 2008.
157. A. Soeda, M. Park, D. Lee et al., "Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α," Oncogene, vol. 28, no. 45, pp. 3949-3959, 2009.
158. E. E. Bar, A. Lin, V. Mahairaki, W. Matsui, and C. G. Eberhart, "Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres," The American Journal of Pathology, vol. 177, no. 3, pp. 1491-1502, 2010.
159. X. Fan, L. Khaki, T. S. Zhu et al., "NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts," STEM CELLS, vol. 28, no. 1, pp. 5-16, 2010.
160. L. Qiang, T. Wu, H.-W. Zhang et al., "HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway," Cell Death and Differentiation, vol. 19, no. 2, pp. 284-294, 2012.
161. J. M. Heddleston, Q. Wu, M. Rivera et al., "Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential," Cell Death and Differentiation, vol. 19, no. 3, pp. 428-439, 2012.
162. S. Zhao, Y. Lin, W. Xu et al., "Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α," Science, vol. 324, no. 5924, pp. 261-265, 2009.
163. A. B. Hjelmeland, Q. Wu, J. M. Heddleston et al., "Acidic stress promotes a glioma stem cell phenotype," Cell Death and Differentiation, vol. 18, no. 5, pp. 829-840, 2011.
164. J. Chiche, M. C. Brahimi-Horn, and J. Pouysségur, "Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer," Journal of Cellular and Molecular Medicine, vol. 14, no. 4, pp. 771-794, 2010.
165. R. Kulshreshtha, M. Ferracin, S. E. Wojcik et al., "A microRNA signature of hypoxia," Molecular and Cellular Biology, vol. 27, no. 5, pp. 1859-1867, 2007.
166. H. Hu and R. A. Gatti, "MicroRNAs: new players in the DNA damage response," Journal of Molecular Cell Biology, vol. 3, no. 3, pp. 151-158, 2011.
167. P. Fasanaro, S. Greco, M. Lorenzi et al., "An integrated approach for experimental target identification of hypoxia-induced miR-210," The Journal of Biological Chemistry, vol. 284, no. 50, pp. 35134-35143, 2009.
168. G. Shen, X. Li, Y.-F. Jia, G. A. Piazza, and Y. Xi, "Hypoxia-regulated microRNAs in human cancer," Acta Pharmacologica Sinica, vol. 34, no. 3, pp. 336-341, 2013.
169. C. Tanase, R. Albulescu, E. Codrici et al., "Circulating biomarker panels for targeted therapy in brain tumors," Future Oncology, vol. 11, no. 3, pp. 511-524, 2015.
170. S. Hara, J. Hamada, C. Kobayashi, Y. Kondo, and N. Imura, "Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney: suppression of HIF-mediated gene expression by HIF-3α," Biochemical and Biophysical Research Communications, vol. 287, no. 4, pp. 808-813, 2001.
171. R. Agrawal, P. Pandey, P. Jha, V. Dwivedi, C. Sarkar, and R. Kulshreshtha, "Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing," BMC Genomics, vol. 15, no. 1, article 686, 2014.
172. S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, inflammation, and cancer," Cell, vol. 140, no. 6, pp. 883-899, 2010.
173. I. F. Parney, J. S. Waldron, and A. T. Parsa, "Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation," Journal of Neurosurgery, vol. 110, no. 3, pp. 572-582, 2009.
174. J. J. Watters, J. M. Schartner, and B. Badie, "Microglia function in brain tumors," Journal of Neuroscience Research, vol. 81, no. 3, pp. 447-455, 2005.
175. W. Roggendorf, S. Strupp, and W. Paulus, "Distribution and characterization of microglia/macrophages in human brain tumors," Acta Neuropathologica, vol. 92, no. 3, pp. 288-293, 1996.
176. L. Yi, H. Xiao, M. Xu et al., "Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma," Journal of Neuroimmunology, vol. 232, no. 1-2, pp. 75-82, 2011.
177. S.-C. Wang, J.-H. Hong, C. Hsueh, and C.-S. Chiang, "Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model," Laboratory Investigation, vol. 92, no. 1, pp. 151-162, 2012.
178. M. Tafani, M. Di Vito, A. Frati et al., "Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma," Journal of Neuroinflammation, vol. 8, article 32, 2011.
179. K. Gabrusiewicz, A. Ellert-Miklaszewska, M. Lipko, M. Sielska, M. Frankowska, and B. Kaminska, "Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas," PLoS ONE, vol. 6, no. 8, Article ID e23902, 2011.
180. E. Tartour, H. Pere, B. Maillere et al., "Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy," Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 83-95, 2011.
181. J. M. Weiss, L. A. Ridnour, T. Back et al., "Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy," The Journal of Experimental Medicine, vol. 207, no. 11, pp. 2455-2467, 2010.
182. R. Albulescu, E. Codrici, I. D. Popescu et al., "Cytokine patterns in brain tumour progression," Mediators of Inflammation, vol. 2013, Article ID 979748, 7 pages, 2013.
183. Q. Lahmar, J. Keirsse, D. Laoui, K. Movahedi, E. Van Overmeire, and J. A. Van Ginderachter, "Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment," Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2015.
184. A. L. Ribeiro Xavier, B. T. Kress, S. A. Goldman, J. R. Lacerda de Menezes, and M. Nedergaard, "A distinct population of microglia supports adult neurogenesis in the subventricular zone," The Journal of Neuroscience, vol. 35, no. 34, pp. 11848-11861, 2015.
185. W. Paulus, W. Roggendorf, and T. Kirchuer, "Ki-M1P as a marker for microglia and brain macrophages in routinely processed human tissues," Acta Neuropathologica, vol. 84, no. 5, pp. 538-544, 1992.
186. M. B. Graeber, B. W. Scheithauer, and G. W. Kreutzberg, "Microglia in brain tumors," Glia, vol. 40, no. 2, pp. 252-259, 2002.
187. W. Zhou, S. Q. Ke, Z. Huang et al., "Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth," Nature Cell Biology, vol. 17, no. 2, pp. 170-182, 2015.
188. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., "CSF-1R inhibition alters macrophage polarization and blocks glioma progression," Nature Medicine, vol. 19, no. 10, pp. 1264-1272, 2013.
189. W. C. Huang, W. H. Chiang, Y. H. Cheng et al., "Tumortropic monocyte-mediated delivery of echogenic polymer bubbles and therapeutic vesicles for chemotherapy of tumor hypoxia," Biomaterials, vol. 71, pp. 71-83, 2015.
190. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
191. A. R. Safa, M. R. Saadatzadeh, A. A. Cohen-Gadol, K. E. Pollok, and K. Bijangi-Vishehsaraei, "Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs," Genes & Diseases, vol. 2, no. 2, pp. 152-163, 2015.
192. M. S. Wicha, S. Liu, and G. Dontu, "Cancer stem cells: an old idea - a paradigm shift," Cancer Research, vol. 66, no. 4, pp. 1883-1890, 2006.
193. A.-M. Enciu, E. Codrici, I. Popescu, S. Mihai, R. Albulescu, and C. Tanase, "Patents in cacer stem cells," Recent Patents on Biomarkers, vol. 5, no. 1, pp. 3-13, 2015.
194. Q. Shen, S. K. Goderie, L. Jin et al., "Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells," Science, vol. 304, no. 5675, pp. 1338-1340, 2004.
195. M. Kioi, H. Vogel, G. Schultz, R. M. Hoffman, G. R. Harsh, and J. M. Brown, "Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice," The Journal of Clinical Investigation, vol. 120, no. 3, pp. 694-705, 2010.
196. J. M. Heddleston, M. Hitomi, M. Venere et al., "Glioma stem cell maintenance: the role of the microenvironment," Current Pharmaceutical Design, vol. 17, no. 23, pp. 2386-2401, 2011.
197. C. Folkins, S. Man, P. Xu, Y. Shaked, D. J. Hicklin, and R. S. Kerbel, "Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors," Cancer Research, vol. 67, no. 8, pp. 3560-3564, 2007.
198. G. L. Semenza, "Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy," Trends in Pharmacological Sciences, vol. 33, no. 4, pp. 207-214, 2012.
199. Y. Xia, H.-K. Choi, and K. Lee, "Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors," European Journal of Medicinal Chemistry, vol. 49, pp. 24-40, 2012.
200. A. Palazon, A. W. Goldrath, V. Nizet, and R. S. Johnson, "HIF transcription factors, inflammation, and immunity," Immunity, vol. 41, no. 4, pp. 518-528, 2014.
201. S. C. Cheng, J. Quintin, R. A. Cramer et al., "mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity," Science, vol. 345, no. 6204, Article ID 1250684, 2014.
202. S. Saeed, J. Quintin, H. H. D. Kerstens et al., "Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity," Science, vol. 345, no. 6204, Article ID 1251086, 2014.
203. S. Coma, A. Shimizu, and M. Klagsbrun, "Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2," Cell Adhesion and Migration, vol. 5, no. 3, pp. 266-275, 2011.
204. F. Pistollato, S. Abbadi, E. Rampazzo et al., "Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma," STEM CELLS, vol. 28, no. 5, pp. 851-862, 2010.
205. D. Tseng, D. A. Vasquez-Medrano, and J. M. Brown, "Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas," British Journal of Cancer, vol. 104, no. 12, pp. 1805-1809, 2011.
206. M. Aubry, M. de Tayrac, A. Etcheverry et al., "From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity," Oncotarget, vol. 6, no. 14, pp. 12094-12109, 2015.
207. K. Petrecca, M.-C. Guiot, V. Panet-Raymond, and L. Souhami, "Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma," Journal of Neuro-Oncology, vol. 111, no. 1, pp. 19-23, 2013.
208. J. Lemée, A. Clavreul, and P. Menei, "Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone," Neuro-Oncology, vol. 17, no. 10, pp. 1322-1332, 2015.
209. S. J. Madsen, C. Christie, S. J. Hong et al., "Nanoparticle-loaded macrophage-mediated photothermal therapy: potential for glioma treatment," Lasers in Medical Science, vol. 30, no. 4, pp. 1357-1365, 2015.
210. S. J. Madsen, H. M. Gach, S. J. Hong, F. A. Uzal, Q. Peng, and H. Hirschberg, "Increased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption," Lasers in Surgery and Medicine, vol. 45, no. 8, pp. 524-532, 2013.
211. J. Dong and Q. Huang, "Targeting glioma stem cells: enough to terminate gliomagenesis?" Chinese Medical Journal, vol. 124, no. 17, pp. 2756-2763, 2011.